Contents
Key findings
- 1There is no randomised, controlled trial of BPC-157 for any outcome in humans. Every efficacy claim rests on rodent studies.
- 2The rodent literature is large — tendon, ligament, muscle, gut, vessels, brain — but the great majority comes from a single group at the University of Zagreb, with limited independent replication.
- 3Where independent labs have looked (tendon cells in culture, some animal models), they have found effects; that supports biological activity, not human benefit.
- 4FDA placed BPC-157 in category 2 of its compounding interim policies in September 2023 over immunogenicity and impurity concerns; the nomination was later withdrawn, which removes it from that list without making it eligible for compounding.
- 5The evidence grade would move to preliminary or promising with a single adequately designed human trial. None with posted results exists on ClinicalTrials.gov at our last check.
Evidence level
Extensive rodent evidence of accelerated healing across many injury models, concentrated in one research group; one small human safety/pharmacokinetic dataset and uncontrolled case reports; no randomised controlled efficacy trial in humans.
Regulatory status
Not FDA-approved. Placed in category 2 of the compounding interim policies on 29 September 2023; on the FDA list current 22 April 2026 it appears among substances previously in category 2 whose nominations were withdrawn by the nominators. Prohibited in sport under WADA S0.
BPC-157 is the most-searched "healing peptide" and the clearest example of a gap between popularity and evidence. Its literature is real and large. Almost none of it is in humans. This analysis lays out what has been shown, in whom, and what remains open.
The question readers actually ask
Does BPC-157 heal tendons, ligaments and muscle in people? The honest answer is: nobody knows, because no one has run the trial that would tell us. What follows explains why that answer is more precise than either "it works" or "it's snake oil".
What BPC-157 is
BPC-157 is a synthetic 15-amino-acid peptide described by its developers as a fragment of a protein found in human gastric juice ("body protection compound"). It has been studied since the early 1990s, principally by a group at the University of Zagreb, in an unusually broad set of rodent injury models[1]. It is stable in gastric acid, which is why oral as well as injected dosing appears in the animal work.
What the animal research shows
Read charitably, the rodent literature is consistent and biologically plausible:
- Tendon and ligament: transected Achilles tendon and medial collateral ligament models heal faster by histology and biomechanics.
- Muscle: crush and transection injuries show improved function and structure.
- Gut: protection against ulcers, colitis, and anastomosis breakdown — the original indication.
- Vessels and nitric oxide: BPC-157 interacts with the NO system and promotes angiogenesis, often invoked as the unifying mechanism.
- Brain and behaviour: effects in rodent models of stroke, seizures and dopamine-related behaviours.
Independent groups have reproduced some findings — for example, a Taiwanese laboratory showed BPC-157 increases tendon-cell outgrowth, survival and migration in culture and in explants[2]. That matters: it supports real biological activity rather than artefact.
Study details: The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
- Study type
- In vitro and rat tendon explant
- Population
- Rat Achilles tendon fibroblasts and explants
- Primary result
- BPC-157 increased fibroblast outgrowth, survival under stress and migration; FAK–paxillin pathway implicated.
- Limitations
- Independent group, but cell/explant work only.
- Year
- 2011
- Source
- Journal of Applied Physiology(link not yet independently re-verified)
Read critically, three features stand out. First, the concentration of publications in one laboratory. Second, the near-uniformity of positive results across wildly different systems, which is unusual for any compound and is either a sign of a remarkable molecule or of methods that reliably find effects. Third, the absence of the step that normally follows a decade of positive animal work: human trials. Reviewers made exactly this point in 2019[3]; the situation has not materially changed.
What the human evidence shows
Very little. As of our last check:
- A small safety and pharmacokinetic dataset in healthy volunteers has been reported, describing tolerability over a short period.
- Uncontrolled case reports and small series — for example, injections for knee pain in a clinic setting — report improvement without a control group.
- No randomised, placebo-controlled trial of any efficacy endpoint has posted results on ClinicalTrials.gov[5].
Uncontrolled reports of pain improvement after an injection cannot separate the peptide from placebo, from the injection itself, or from time. That is not a criticism of the clinicians reporting them; it is a description of what the study design can and cannot show.
Safety: what is and isn't known
There is no signal of acute toxicity in the animal work or the small human dataset. That is not the same as evidence of safety, for three reasons:
- No long-term human data. Chronic use, drug interactions and rare harms are unstudied.
- Mechanism cuts both ways. A compound that promotes angiogenesis and cell migration is, in principle, a compound that could feed a tumour. This has not been studied in people, which is one of the concerns the FDA cited.
- Product quality. BPC-157 is sold only as an unregulated product. Independent testing of such products has found under-dosing, mislabelling and contamination (see our certificate of analysis analysis). Whatever the molecule does, the vial may not contain it.
Regulatory position
BPC-157 is not FDA-approved for any use and, to our knowledge, has never been in formal U.S. clinical development.
Its compounding status has moved. On 29 September 2023 the FDA placed BPC-157 in category 2 of the interim compounding policies — substances the agency judges may present significant safety risks — citing possible immunogenicity for certain routes of administration, complexities with peptide-related impurities and active-ingredient characterisation, and "no, or only limited, safety-related information for the proposed routes of administration". On the FDA list current at 22 April 2026, BPC-157 no longer appears in category 2 itself; it appears on the accompanying list of substances previously in category 2 whose nominations were withdrawn by the nominators[4].
It is prohibited in sport under WADA's S0 category for non-approved substances[6].
Why the grade is preclinical, and what would change it
Our evidence level for BPC-157 for recovery and tissue repair is preclinical: cell and animal research only, no adequate human evidence. Specifically:
| Claim | Best evidence | Grade |
|---|---|---|
| Accelerates tendon/ligament healing | Rodent transection models; tendon-cell culture | Preclinical evidenceNo human trial |
| Heals muscle injury | Rodent crush/transection models | Preclinical evidenceNo human trial |
| Protects or heals the gut | Rodent ulcer/colitis/anastomosis models | Preclinical evidenceNo human trial |
| Reduces joint pain in people | Uncontrolled clinic case series | Preclinical evidenceUncontrolled human reports only |
| Safe for long-term human use | One small short-term dataset | Unsupported evidenceInsufficient data |
A single adequately powered, randomised, placebo-controlled human trial with a functional endpoint — return to sport after a defined tendon injury, say — would move the grade to preliminary or promising depending on quality and result. We monitor ClinicalTrials.gov for exactly that and will update this analysis and the BPC-157 profile when it appears.
Where to go next
- BPC-157 profile — the at-a-glance summary, FAQ and key studies.
- BPC-157 vs TB-500 — the two "healing peptides" side by side.
- Recovery and tissue repair hub — how every peptide we cover grades for healing.
- How to read peptide research — the five questions this analysis applied.
Frequently asked questions
- Has BPC-157 ever been tested in humans?
- Only in a small safety/pharmacokinetic dataset and uncontrolled reports. There is no randomised, placebo-controlled efficacy trial.
- Why does BPC-157 have so many studies if it doesn't work?
- We don't know that it doesn't work — we know it hasn't been tested properly in people. The many studies are almost all in rodents and mostly from one research group.
- Is BPC-157 oral or injectable in the studies?
- Rodent studies have used both routes and report effects with each. That does not establish which, if either, does anything in humans.
- Why did the FDA restrict BPC-157 compounding?
- In September 2023 FDA placed it in category 2, citing possible immunogenicity for certain routes of administration, complexities with peptide-related impurities and API characterisation, and no or only limited safety information for the proposed routes.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications Current Neuropharmacology, 2016.
Review
Result: Summarises the group's rodent findings across gastrointestinal, musculoskeletal, vascular and CNS models.
Limitations: Authored by the originating laboratory; no human efficacy data.
↑ back to text - 2.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Journal of Applied Physiology, 2011.
PreclinicalRat Achilles tendon fibroblasts and explants
Result: BPC-157 increased fibroblast outgrowth, survival under stress and migration; FAK–paxillin pathway implicated.
Limitations: Independent group, but cell/explant work only.
↑ back to text - 3.
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Cell and Tissue Research, 2019.
Review
Result: Concludes rodent evidence is consistent but human trials are absent and needed.
↑ back to text - 4.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 list) U.S. Food and Drug Administration, 2026.
Regulatory source
Result: BPC-157 was placed in category 2 on 29 September 2023 and, on the list current 22 April 2026, appears among substances previously in category 2 whose nominations were withdrawn by the nominators.
↑ back to text - 5.
Clinical trials of BPC 157 (search) ClinicalTrials.gov.
Trial registry
Result: No registered trial with posted efficacy results in humans at our last check.
↑ back to text - 6.
The Prohibited List World Anti-Doping Agency, 2026.
Regulatory source
Result: BPC-157 prohibited at all times (S0).
↑ back to text - 7.
Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans JAMA, 2006.
Systematic review
Result: Only about a third of highly cited animal studies translated to human RCTs; about 10% to approved interventions.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
